Citi analyst Joel Beatty raised his price target for Novavax shares to $18 from $10 ahead of results from four vaccine trials expected to come in Q3. Data to date are supportive of the probability of success for Novavax's novel vaccines, Beatty tells investors today in a research note. He believes the company has "sizable" market opportunities in respiratory syncytial virus and seasonal influenza. The analyst views the upcoming Phase 2 RSV trial in elderly patients as the biggest potential catalyst for shares. He keeps a Buy rating on Novavax. The stock closed yesterday down 44c to $10.91.